Frequently asked questions about Ipamorelin — answered from the published record.

Ipamorelin acts as a selective agonist of the ghrelin receptor (GHS-R1a), triggering the anterior pituitary to release GH in discrete pulses. At doses more than 200-fold above the GH-releasing ED₅₀ in rats, it produces no significant elevation of ACTH, cortisol, prolactin, FSH, LH, or TSH.^[1] GH pulse peak occurs at 15–40 minutes post-injection; return to baseline within approximately 3 hours.^[2]

The main pharmacological concern is GH-independent adiposity: Lall et al. 2001 found that chronic GHS administration including ipamorelin increased fat pad weights regardless of GH status in mice, via a non-GH mechanism.^[8] Transient injection-site reactions and mild headache-analog signals appear in rodent studies. Regulatory concerns include WADA prohibition (S2, at all times)^[9] and FDA prohibition from compounding pharmacy use after October 2024.^[16]

In preclinical models the result depends on the model context. Bone and body-composition studies show increased body weight alongside lean mass accretion at studied doses.^[3][4] Lall et al. 2001 found increased fat pad weights through GH-independent mechanisms in mice, not offset by GH-mediated lipolysis in that model.^[8] Net weight change is not uniform across model types and dose ranges.

Ipamorelin does not directly stimulate testosterone production. The LH/FSH gonadotropin axis is not significantly engaged by GHS-R1a agonism at studied doses — FSH and LH remained unchanged in the comprehensive hormonal panel conducted by Raun et al. 1998.^[1] No direct testosterone pathway is activated; any downstream testosterone change would require an independent endocrine mechanism not documented in the published ipamorelin record.

Tesamorelin is FDA-approved for HIV-associated lipodystrophy and has clinical trial data showing approximately 15–18% visceral fat reduction at 26–52 weeks.^[13][17] Ipamorelin has preclinical selectivity data and one incomplete Phase 2 trial. They act on different receptor classes (GHRH-R vs. GHS-R1a), have not been tested head-to-head, and address different research endpoints. No comparative superiority is established in the published record.

Both compounds avoid the cortisol/prolactin elevation seen with GHRP-2, GHRP-6, and hexarelin. Ipamorelin's selectivity was demonstrated across doses 200-fold above the GH-releasing ED₅₀ in rats;^[1] sermorelin's adverse-event profile at studied human doses also shows no significant cortisol, prolactin, or insulin elevation.^[14] Direct head-to-head safety comparisons in a single controlled study do not appear in the reviewed literature.

Animal studies report GH-mediated lipolytic signaling at adipose receptors that could contribute to visceral fat reduction; however, Lall et al. 2001 found that GH secretagogues including ipamorelin can increase fat mass through GH-independent mechanisms at chronic doses in mouse models.^[8] No human visceral fat reduction study for ipamorelin exists in the reviewed literature. The body-composition effect is model-dependent.

Co-administration is studied for additive GH pulse amplitude via dual-pathway activation. CJC-1295 (GHRH analog acting on GHRH-R via Gαs/cAMP) primes somatotrophs and extends GH pulse duration; ipamorelin (GHS-R1a agonist) triggers acute GH exocytosis per primed cell.^[10][11] The two pathways are mechanistically orthogonal. Human CJC-1295 data shows 2–10-fold GH elevation in healthy adults;^[10] ipamorelin dual-pathway framing is research-context only.

Published preclinical protocols vary: once daily to three-times-daily injection intervals appear across ipamorelin bone and body composition studies.^[3][4] CJC-1295 in human trials was administered as single or multiple SC doses across weeks given its 5.8–8.1 day half-life.^[10] No clinically recommended injection frequency exists — Ipamorelin has no approved human dosing protocol.

In rodent studies: GH pulse changes are measured within 15–30 minutes of injection;^[2] body weight and bone formation changes are assessed over 3-month treatment windows in bone studies.^[4] The Sinha 2020 review references lean mass and fat reduction endpoints over weeks to months in GHS body composition studies.^[12] No Ipamorelin-specific time-to-endpoint study in humans appears in the reviewed record.

Combined-use studies in the reviewed literature note similar tolerability to ipamorelin alone. CJC-1295-specific concerns from human trials include injection-site reactions; no major neuroendocrine disruption was reported at studied doses in healthy adults.^[10] The Lall 2001 GH-independent adiposity caveat applies to GHS class effects broadly.^[8] No approved co-administration protocol exists; all combined use is outside regulated frameworks.

Preclinical models study GHRH + GHRP co-administration to assess additive GH-pulse effects via the two complementary receptor pathways (GHRH-R and GHS-R1a).^[14] Sermorelin's 11–12 minute half-life and ipamorelin's ~2-hour half-life create different priming dynamics than the longer-acting CJC-1295 combination. No approved co-administration protocol exists for either combination; framing is research-context only.

No. Ipamorelin has not received FDA approval for any human indication. The Phase 2 clinical trial (NCT00672074, Helsinn Therapeutics) for post-operative ileus completed without an NDA submission.^[15] The FDA Pharmacy Compounding Advisory Committee voted against adding ipamorelin acetate to the 503A bulk drug substances list in October 2024, prohibiting compounding pharmacy use under current FDA policy.^[16]

Ipamorelin is a pentapeptide (five amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH₂), molecular weight 711.87 Da, synthesized by Novo Nordisk under the designation NNC 26-0161. It is classified as a growth hormone secretagogue that selectively binds GHS-R1a receptors on anterior pituitary somatotrophs and hypothalamic neurons to stimulate pulsatile GH release.^[1]

Ipamorelin binds GHS-R1a (ghrelin receptor) in the hypothalamus and anterior pituitary to amplify pulsatile GH secretion via Gq/11-coupled phospholipase C and intracellular calcium mobilization. It simultaneously suppresses somatostatin tone. Unlike earlier GHRPs, it produces GH pulses without the cortisol, prolactin, or aldosterone elevations seen with GHRP-2, GHRP-6, or hexarelin at stimulating doses.^[1]

Ipamorelin's selectivity profile differs from full ghrelin agonism, which is orexigenic (appetite-stimulating). Single-dose administration in Venkova et al. 2009 produced no significant food intake change at 48 hours in rodent models.^[5] The endogenous ghrelin appetite signal does not appear to be carried through fully by ipamorelin's selective GHS-R1a engagement at single or low doses.

Appetite stimulation is a known downstream effect of full ghrelin receptor agonism. Ipamorelin's preclinical data specifically examined appetite-axis sparing: no food intake increase was observed after single-dose administration in surgical models.^[5] Appetite effects were observed only with repetitive dosing in energy-depleted post-surgical animals — a context-specific finding, not a general orexigenic profile. Minimal appetite effect vs. endogenous ghrelin is documented.^[5]

Rodent pharmacokinetic data places ipamorelin's plasma half-life at approximately 2 hours.^[2] GH pulse elevation extends over a 3-hour post-injection window; the compound itself is predominantly cleared via urinary excretion with 60–80% recoverable intact. Free-acid metabolites persist in urine after the parent compound clears — the basis for the WADA detection window established in Semenistaya et al. 2015.^[9]

Ipamorelin mimics ghrelin at GHS-R1a, activating Gq/11-coupled phospholipase C in somatotroph cells to generate IP₃ and mobilize intracellular Ca²⁺, triggering GH vesicle exocytosis. It also suppresses hypothalamic somatostatin, amplifying pulse amplitude beyond direct receptor activation alone.^[1] Each pulse peaks at 15–40 minutes post-SC-injection and returns to baseline within approximately 3 hours.^[2]

Sermorelin is a GHRH 1-29 fragment acting on the GHRH receptor (GHRH-R) via Gαs/cAMP/PKA — plasma half-life 11–12 minutes.^[14] Ipamorelin is a ghrelin mimetic acting on GHS-R1a via Gq/Ca²⁺ — plasma half-life approximately 2 hours.^[2] Distinct receptor classes, distinct G-protein pathways, distinct half-lives. Both avoid cortisol/prolactin elevation at studied doses; the selectivity data depth is greater for ipamorelin (200-fold dose range; full hormonal panel).^[1]

Yes. Ipamorelin is a five-amino-acid peptide (pentapeptide): Aib-His-D-2-Nal-D-Phe-Lys-NH₂, molecular weight 711.87 Da, synthesized by Novo Nordisk as part of a systematic search for selective growth hormone secretagogues.^[1] Its synthesis preceded the discovery of endogenous ghrelin (1999), making it a pharmacological tool that preceded identification of its natural ligand.

Preclinical protocols vary administration timing without establishing a definitive optimum. Fasted-state and pre-sleep timing are both studied across GHS research protocols. The Andersen et al. 2001 bone study used three-times-daily SC injection over 3 months without specifying time-of-day optimization.^[4] Optimal timing for GH-pulse maximization in animal models varies by endpoint and co-agent; no human protocol exists for this compound.

Both male and female animal subjects appear in published ipamorelin studies. The Johansen 1999 bone study and Andersen 2001 bone protection study used adult female rats;^[3][4] the Jiménez-Reina 2002 somatotroph plasticity study used young female rats.^[7] Sex-specific differences in GH secretion are a documented variable: ghrelin receptor deficiency in adult female (but not male) mice reduces pulsatile GH secretion, indicating female-specific receptor sensitivity to GHS-R1a modulation.^[7]

GH-mediated fluid retention is a known class effect for GH-elevating interventions. Ipamorelin's physiological-range GH pulses — bounded, returning to baseline within ~3 hours per pulse — produce a lower edema signal than direct recombinant GH administration in rodent study observations. Mild fluid retention is a recognized research-model observation for GH-axis modulation generally; minimal edema is reported at ipamorelin's studied dose ranges.

No head-to-head controlled study comparing ipamorelin and sermorelin on a shared outcome measure appears in the reviewed literature. Mechanistically: ipamorelin's GHS-R1a selectivity avoids cortisol/prolactin elevation across a wider demonstrated dose range;^[1] sermorelin's GHRH-R mechanism supports tonic GH secretion patterns with an 11–12 minute half-life suited to GHRH-pattern mimicry.^[14] Neither compound has an approved human indication; compound-level preference is not supported by the published record.

In rat models, GH pulse onset is measured within 15–30 minutes of injection.^[2] GI motility changes (bowel movement, gastric emptying) are observed within hours in post-surgical models.^[5][6] Body-composition and bone formation endpoints in longer studies are assessed over 4–12 week treatment windows.^[3][4] No human endpoint timeline exists in the published record for ipamorelin specifically.

Ipamorelin amplifies pulsatile GH secretion from the anterior pituitary by binding GHS-R1a and mobilizing intracellular calcium in somatotrophs, while suppressing hypothalamic somatostatin tone. GH area-under-curve increases of 2–10-fold relative to baseline are studied at various doses and species^[10][11] — the CJC-1295 human trial data provides the clearest quantification for this class, with ipamorelin's preclinical selectivity as the GHS-R1a reference.^[1]

Research applications include: GH-deficiency and growth deficit models (bone elongation and somatotroph plasticity studies^[3][4][7]); post-surgical GI recovery (Venkova 2009, Greenwood-Van Meerveld 2012, NCT00672074 clinical trial^[5][6][15]); body composition in GH-axis-deficient models;^[8][12] receptor pharmacology selectivity profiling as a reference GHRP;^[1] and anti-doping metabolite characterization for WADA detection.^[9]

CJC-1295 (GHRH analog) activates GHRH-R via Gαs/cAMP to prime somatotroph cells and extend GH pulse duration; ipamorelin activates GHS-R1a via Gq/Ca²⁺ to trigger acute GH exocytosis. The two pathways are mechanistically orthogonal — GHRH increases the proportion of somatotrophs releasing GH while ipamorelin increases GH release per releasing cell. Human CJC-1295 data shows 2–10-fold GH elevation and preserved pulsatile architecture.^[10][11] Ipamorelin's contribution to the combined model is the acute GHS-R1a pulse layer.